公开(公告)号：US20240018269A1

公开(公告)日：2024-01-18

申请号：US18213344

申请日：2023-06-23

Applicant: MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED ,  GENMAB A/S

Inventor： Phillip Mark HOGARTH ,  Bruce David WINES ,  Halina Mary TRIST ,  Sandra Elizabeth ESPARON ,  Alicia Michelle CHENOWETH

IPC: C07K16/42 ,  C07K16/40 ,  C07K16/44

CPC classification number: C07K16/4291 ,  C07K16/40 ,  C07K16/44 ,  C07K2317/53 ,  C07K2317/72 ,  C07K2317/524 ,  C07K2317/76 ,  C07K2317/92

Abstract: Immunotherapeutic proteins comprising at least one heavy chain polypeptide derived from an IgG2 antibody are disclosed, wherein the heavy chain polypeptide comprises at least constant heavy domains 2 and 3 (CH2 and CH3) and the lower hinge, and the sequence of the lower hinge comprises a mutation enabling the immunotherapeutic protein to bind to and/or activate FcγRIIb. The immunotherapeutic protein is suitable for use in methods of treating diseases or conditions wherein, for example, the activation of FcγRIIb (ie for recruitment of the inhibitory functions of FcγRIIb) is beneficial, such as allergic diseases.

公开(公告)号：US20230322947A1

公开(公告)日：2023-10-12

申请号：US17950350

申请日：2022-09-22

Applicant: GENMAB A/S

Inventor： Aran Frank LABRIJN ,  Joyce I. MEESTERS ,  Joost J. NEIJSSEN ,  Edward Norbert VAN DEN BRINK ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/10 ,  C07K16/36 ,  C07K16/00 ,  C07K16/32 ,  C07K16/12

CPC classification number: C07K16/40 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/1063 ,  C07K16/36 ,  C07K16/00 ,  C07K16/2809 ,  C07K16/32 ,  C07K16/1271 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/53 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/92 ,  C07K2317/41 ,  C07K2317/74 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/24 ,  C07K2317/71 ,  A61K2039/505

Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

公开(公告)号：US11613575B2

公开(公告)日：2023-03-28

申请号：US16544376

申请日：2019-08-19

Applicant: GENMAB A/S

Inventor： Edward Norbert Van Den Brink ,  Joost J. Neijssen ,  Aran Frank Labrijn ,  Joyce Meesters ,  Janine Schuurman ,  Isil Altintas ,  Paul Parren ,  Rik Rademaker

IPC: A61P35/00 ,  C07K16/28 ,  C07K16/32 ,  C07K16/10 ,  C07K16/42 ,  G01N33/68 ,  A61K39/00

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US11608383B2

公开(公告)日：2023-03-21

申请号：US17559938

申请日：2021-12-22

Applicant: GENMAB A/S

Inventor： Brian Elliott ,  Tahamtan Ahmadi ,  Christopher W. L. Chiu ,  Esther C. W. Breij ,  Ida Hiemstra ,  Maria N. Jure-Kunkel

IPC: A61K39/40 ,  A61K39/395 ,  C07K16/28 ,  A61K31/454 ,  C07K16/00

Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.

公开(公告)号：US11548952B2

公开(公告)日：2023-01-10

申请号：US17560006

申请日：2021-12-22

Applicant: GENMAB A/S

Inventor： Brian Elliott ,  Tahamtan Ahmadi

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/555 ,  A61K31/573 ,  A61K31/7072

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).

公开(公告)号：US20220396629A1

公开(公告)日：2022-12-15

申请号：US17825202

申请日：2022-05-26

Applicant: GENMAB A/S

Inventor： Paul PARREN ,  Janine Schuurman ,  Tom Vink ,  Willem Karel Bleeker ,  Jan Van De Winkel ,  Patrick Van Berkel ,  Frank Beurskens

IPC: C07K16/28

Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.

公开(公告)号：US20220387485A1

公开(公告)日：2022-12-08

申请号：US17771784

申请日：2020-11-06

Applicant: Genmab A/S

Inventor： Reshma A RANGWALA ,  Esther C,W. BREIJ ,  Sandra VERPLOEGEN ,  Oyewale O. ABIDOYE ,  Leonardo V. NICACIO

IPC: A61K33/243 ,  A61K31/555 ,  A61K47/68 ,  A61P35/00

Abstract: The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.

公开(公告)号：US20220380464A1

公开(公告)日：2022-12-01

申请号：US17739923

申请日：2022-05-09

Applicant: GENMAB A/S

Inventor： Rik RADEMAKER ,  Isil ALTINTAS ,  Patrick ENGELBERTS ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C07K16/32

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US11130819B2

公开(公告)日：2021-09-28

申请号：US17228023

申请日：2021-04-12

Applicant: GENMAB A/S

Inventor： David Satijn ,  Esther C. W. Breij ,  Bart E. C. G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79 ,  A61K39/00

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20210277133A1

公开(公告)日：2021-09-09

申请号：US17172700

申请日：2021-02-10

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Ugur SAHIN ,  Friederike GIESEKE ,  Alexander MUIK ,  Christian GRUNWITZ

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.